TARS

Insider Trades

Name	Value	Action	Price	Current Price
Neervannan SeshadriChief Operating Officer $200k3k shares SellMar 20, 2026 $66.75 --
Azamian Bobak R.Director, Officer: President/CEO And Board Chair $802k12k shares SellMar 19, 2026 $67.00 --
Neervannan SeshadriChief Operating Officer $307k4.6k shares SellMar 19, 2026 $67.00 --
Mottiwala AzizChief Commercial Officer $297k4.4k shares SellMar 19, 2026 $67.00 --
Wahl BryanGeneral Counsel $283k4.2k shares SellMar 19, 2026 $67.00 --
Whitfield Dianne C.Chief Human Resources Officer $280k4.2k shares SellMar 19, 2026 $67.00 --

News

globenewswire.comTarsus to Participate in Upcoming Investor Conferencesglobenewswire.comMay 28

seekingalpha.comTarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raiseseekingalpha.comMay 15

globenewswire.comTarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americansglobenewswire.comMay 14

seekingalpha.comTarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.comMay 12

globenewswire.comTarsus to Participate in Upcoming Investor Conferencesglobenewswire.comMay 7

Trade TARS

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.

CEO: Bobak R. Azamian
IPO Date: Oct 16, 2020

Market Data

Open: $63.38
High: $64.24
Low: $62.37
Volume: 375.6K
Avg Volume: 612.5K
52W High: $85.25
52W Low: $38.51

Valuation

Market Cap: $2.7B
Enterprise Value: $2.7B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-22M
Revenue: $451M
Net Income: $-66M
Cash: $184M
Debt: $94M

Events

EarningsAug 6

EPS est. -0.22